Home › Cancro ovarico › Michigan
Studi clinici su Cancro ovarico nello stato di Michigan
50 studi su Cancro ovarico cercano partecipanti presso sedi nello stato di Michigan.
Città nello stato di Michigan
- Detroit26 studi
- Grand Rapids24 studi
- Ann Arbor11 studi
- Kalamazoo5 studi
- Farmington Hills4 studi
- Livonia4 studi
- Canton4 studi
- Warren4 studi
- Lansing3 studi
- Troy3 studi
- Flint3 studi
- Saginaw3 studi
- Clinton Township3 studi
- Dearborn3 studi
Testo ufficiale dello studio (inglese)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- e altri 37
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06270706A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07189871First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06799065A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0101 - Barbara Ann Karmanos Cancer Institute, Detroit
- Site 0228 - Corewell Health Medical Group West, Grand Rapids
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05128825Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Henry Ford Health, Detroit
- Valley OB-GYN Clinic, Saginaw
In reclutamentoStudio osservazionale
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05051722A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Donne · Aggiornato il 24 set 2026 · NCT04590326Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Grand Rapids
In reclutamentoFase 2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Karmanos Cancer Institute - Detroit /ID# 277085, Detroit
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Karmanos Cancer Institute, Detroit
- West Michigan Cancer Center, Kalamazoo
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213791A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Michigan Health System, Ann Arbor
In reclutamentoFase 2
Età da 18 a 99 · Donne · Aggiornato il 15 set 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Henry Ford Cancer - Detroit, Detroit
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 15 set 2026 · NCT07214779Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 14 set 2026 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06293898A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06400472The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- e altri 13
In reclutamentoVolontari sani benvenuti
Età da 45 a 75 · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- University of Michigan, Ann Arbor
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 26 ago 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1
Età 15 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- C S Mott Children's Hospital, Ann Arbor
In reclutamentoFase 1/2
12 Months – 30 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04851119Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Detroit
In reclutamentoFase 1/2
Età da 18 a 130 · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT05797168Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University of Michigan Rogel Cancer Center, Ann Arbor
- Henry Ford Hospital, Detroit
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- e altri 1
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT07001748A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Karmanos Cancer Center, Detroit
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07470853Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 ago 2026 · NCT05985655A Study of PHST001 in Advanced Solid Tumors
- University of Michigan Rogel Cancer Center, Ann Arbor
- START Center for Cancer Research - Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT06840886A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06242470A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- e altri 23
In reclutamento
Età da 35 a 50 · Donne · Aggiornato il 7 ago 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- e altri 49
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT06580314Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- START - Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07444814Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 ago 2026 · NCT05579366First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 6 lug 2026 · NCT07226427Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Trinity Health St. Joseph Mercy Ann Arbor, Ann Arbor
- Corewell Health, Grand Rapids
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 2 lug 2026 · NCT06819007A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Henry Ford Health Hospital, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT05377996A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Grand Rapids
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT04641247Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
- BAMF Health, Grand Rapids
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 giu 2026 · NCT07219238Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.